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Oxidative stress is an imbalance between oxidants (reactive oxygen and nitrogen species) and
antioxidants that may affect lipids, DNA, carbohydrates and proteins. The lung is continuously
exposed to endogenous and exogenous oxidants (cigarette smoke, mineral dust, ozone, radia-
tion). Reactive oxygen and nitrogen species are mainly produced by phagocytes as well as by
polymorphonuclear, alveolar, bronchial and endothelial cells. A potential role of oxidative
stress in the pathogenesis of diffuse lung diseases (particularly idiopathic pulmonary fibrosis)
has been demonstrated. Increased oxidant levels and decreased antioxidant defences can
contribute to the progression of idiopathic pulmonary fibrosis and other diffuse lung diseases.
The growing number of papers on the different aspects of oxidant/antioxidant imbalance in
diffuse lung diseases in the last decade reflects increasing interest in this topic and suggests
that specific DLDs may be characterized by specific patterns of oxidation and antioxidant
responses. The study of oxidative stress can provide insights into etiopathogenesis and favour
the discovery of new treatments. In this review of the literature on oxidants and antioxidantsspecies; RNS, reactive nitrogen species; BAL, bronchoalveolar lavage; Ssc, pulmonary fibrosis asso-
iopathic pulmonary fibrosis; DLD, diffuse lung diseases; UIP, usual interstitial pneumonia; DIP, des-
EAA, extrinsic allergic alveolitis; COPD, chronic obstructive pulmonary disease; DNPH,
ide; CO2, carbon dioxide; H2O2, hydrogen peroxide; FVC, forced vital capacity; MMPs, matrix met-
r superoxide dismutase; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen
N-acetylcysteine; PAI-1, plasminogen activator inhibitor 1; MAPK, mitogen-activated protein kinase;
ubunit-related factor 2; NF-kB, nuclear factor-kB; Keap1, Kelch-like enoyl-CoA hydratase-associated
wth factor beta.
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Definition of diffuse lung diseases and oxidative
stress
Diffuse lung diseases (DLD) are a heterogeneous group of
lung disorders with different aetiologies that evolve
towards pulmonary fibrosis of variable severity.1e3 They
are characterized by various pathogenetic mechanisms:
sarcoidosis and lung diseases involving connective tissue
are systemic immunoinflammatory diseases, whereas idio-
pathic pulmonary fibrosis (IPF) is a severe epithelial/
fibroblastic disorder limited to the lung.4,5 IPF is charac-
terized by rapid progression to diffuse fibrosis which
destroys lung parenchyma. The aetiology of this disease is
still unknown, although there is evidence that cellular
redox status and oxidative stress contribute to pro-
gression.6e15 Reactive oxygen species (ROS) and reactive
nitrogen species (RNS) are free radicals generated physio-
logically during oxidative phosphorylation.9,12,16 They have
various physiological roles and are removed rapidly from
the body: their persistence can cause cell dysfunction and
cell death.9 Defence mechanisms against oxidants involve
enzyme and non-enzyme antioxidant systems. An imbal-
ance between generation of ROS/RNS and antioxidant
defences leads to a negative condition known as oxidative/
nitrosative stress7,9 in which cell antioxidants are insuffi-
cient to keep ROS/RNS below a toxic threshold due to
excessive production of ROS/RNS and/or loss of cell anti-
oxidant defences (Fig. 1).7 Oxidative/nitrosative stress can
affect proteins, lipids, carbohydrates and nucleic acids
that are the main components of cells.17e26
Oxidizing agents can be produced endogenously by
metabolic reactions (including activation of phagocytes or
mitochondrial electron transport during respiration) or
exogenously by cigarette smoking, toxins, pollution, radia-
tion, drugs and other causes (Table 1).20,25 During inflam-
matory processes, activated macrophages and neutrophilscan release a great amount of hydrogen peroxide and
superoxide via the phagocytic isoform of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase. The
massive production of antimicrobial and tumoricidal ROS in
an inflammatory environment plays an important role in
bodily defences but when inflammation becomes chronic it
induces persistent activation of macrophages and neutro-
phils that become a persistent source of oxidative damage
of DNA and cell components.25,26 Chronic inflammation-
induced production of ROS/RNS in the lung may predispose
individuals to lung diseases.20,21 Activated macrophages
and neutrophils dominate inflammatory responses in DLD
and are particularly elevated in bronchoalveolar lavage
(BAL) of patients with IPF, sarcoidosis and pulmonary
fibrosis associated with systemic sclerosis (Ssc).16,17,22
In IPF, the pulmonary redox imbalance is due to an
increase in oxidants associated with extracellular gluta-
thione deficiency7e9,13 which has been associated with
disease progression (smokers with IPF are reported to have
worse survival and severity-adjusted survival than non-
smokers with IPF).14 Very recently Daniil et al. determined
oxidative burden in serum of IPF patients by a simple
reproducible method based on analysis of total hydroper-
oxides.15 They concluded that systemic oxidative stress
levels were significantly higher in IPF patients than in
controls and negatively correlated with lung function
parameters (forced vital capacity and diffuse lung capacity
for carbon monoxide) and dyspnoea severity.15
Imbalance between oxidants and antioxidants is a path-
ogenetic mechanism also recognized in other DLD, such as
pulmonary fibrosis associated with systemic sclerosis (Ssc),
sarcoidosis and pneumoconiosis. Oxidative stress is thought
to induce progression in Ssc by interaction of oxygen
radicals with vascular endothelium components and fibro-
blasts.22e24 The description of oxidant/antioxidant balance
in the lungs and evidence of its involvement in the patho-
genesis of different DLDs is the main topic of the present
review.
Figure 1 Reactions of superoxide (O2
), hydrogen peroxide (H2O2), and nitric oxide (NO

) and cell injury. The activation of
inflammatory cells results in generation of NO and other RNS by nitric oxide synthase. The major antioxidant enzymes scavenging
superoxide and hydrogen peroxide are: superoxide dismutases (copper, zinc-SOD, manganese-SOD, extracellular-SOD); catalase
(CAT), thioredoxins (TRXs), peroxyredoxins (PRXs), glutaredoxins (GRXs) [intracellular origin]; glutathione peroxidase (GPXe),
peroxyredoxin IV (PRXIV) [extracellular origin], and glutathione antioxidant system [intra- and extracellular origins].
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 Pathophysiological role of ROS and RNS
 Effects of ROS/RNS in the pathogenesis of DLD and BAL
findings
Because of their anatomy, location and function, the lungs
are highly susceptible to oxidative damage. The main ROS/
RNS implicated in the oxidative-induced damage are listed
in Table 2.9 In non-phagocytic cells, mitochondria are the
main source of ROS, but smooth endoplasmic reticulum and
microsomes may also produce free radicals.25 Moderate
physiological levels of ROS are important to modulate cell
functions such as apoptosis, gene expression, signal trans-
duction and defence against pathogens.26 Up to 1% of the
mitochondrial electron flow leads to formation of super-
oxide anion under normal conditions. Any interference withTable 1 Exogenous and endogenous sources of oxidants
(ROS/RNS).
Exogenous sources Endogenous sources
 Cigarette smoke
 Exogenous toxins
 Pollution
 Hyperoxia
 Radiation
 Carcinogens
 Drugs
 Inflammatory cells
 Fibroblast
 Epithelial cells
 Endothelial cells
 Respiratory chain
 Xantine and NADPH oxidaseelectron transport can increase superoxide produc-
tion.9,25,26 Under physiological conditions reactive oxygen
species induce secretion of mucus, remodel extracellular
matrix and blood vessels, regulate expression of anti-
proteases and trigger alveolar repair responses, apoptosis
and proliferation, modulating immunological responses in
the lung.9
Reactive nitrogen species are oxidant molecules that may
regulate cell survival. Nitric oxide (NO) is an endothelial
vasorelaxant with many biochemical effects produced
through activation of NO synthases.19 Most NO-derived
species interact with glutathione and other thiols, oxidizing
them to nitrosated thiols. Peroxynitrite-mediated reactions
are enhanced by carbon dioxide (CO2).
19Table 2 Main reactive oxygen and nitrogen species.
Reactive oxygen
species (ROS)
Reactive nitrogen
species (RNS)
 Superoxide (O2)
 Hydrogen peroxide (H2O2)
 Hydroxyl radical (HO)
 Peroxyl radical (RO2 )
 Alkoxyl radical (RO)
 Hydroperoxyl radical (HO2 )
 Singlet oxigen (1O2)
 Ozone (O3)
 Nitric oxide (NO)
 Nitrogen dioxide (NO2)
 Nitrous acid (HNO2)
 Dinitrogen tetroxide (N2O4)
 Dinitrogen trioxide (N2O3)
 Peroxynitrite (ONOO)
 Peroxynitrous acid (ONOOH)
 Alkyl peroxynitrites (ROONO)
 Nitronium cation (NO2þ)
 Nitryl chloride (NO2Cl)
1248 E. Bargagli et al.ROS/RNS released by phagocytes are involved in lung
tissue damage in interstitial lung diseases.9 Increased acti-
vation and abundance of inflammatory cells in smoking-
related lung diseases, IPF and pneumoconiosis may explain
the high levels of hydroxyl radical and superoxide anion
concentrations in these diseases.19,27 In 1987 it was
demonstrated that neutrophils, macrophages and eosino-
phils from bronchoalveolar lavage of IPF patients over-
produce ROS causing epithelial injury.11 The crucial function
of nitrosyl-induced stress in DLD and enhanced expression of
inducible nitric oxide synthase in lung tissue of patients with
silicosis, granulomatous lung diseases and histiocytosis was
reported by several authors.28,29 Oxidative-mediated lung
and vascular injury has also been documented in patients
with Ssc, who also showed elevated levels of oxidants:
hydroperoxides are abundant in serum of Ssc patients and
their concentrations are correlated with clinical parameters
and microvascular impairment.30 Rahman and MacNee
demonstrated that increased ROS/RNS levels play a major
role in inflammation through activation of transcription
factors (i.e. nuclear factor-kB, NF-kB), signal transduction
and gene expression of proinflammatory mediators.31 ROS/
RNS also regulate many proinflammatory and profibrotic
cytokines involved in lung fibrogenesis and in tissue damage
occurring in DLD (see the section ‘‘Interactions of ROS/RNS
with mediators of diffuse lung diseases’’).9
The most widely studied oxidative stress-induced modi-
fication of proteins is the formation of carbonyl groups on
amino acid residues. Carbonyls are considered a biomarker
of oxidative stress and used to quantify oxidative damage in
polypeptide chains.17e21 Analysis of oxidative stress prod-
ucts in bronchoalveolar lavage demonstrated significantly
higher carbonylated protein content in patients with
diffuse lung diseases than in controls, with an imbalance
between oxidants and antioxidants (Fig. 2).22,32 Proteomic
analysis of BAL protein targets of carbonylation in DLD
revealed that IPF patients had more carbonylated proteins
than sarcoidosis, Ssc patients and controls.22 CarbonylationFigure 2 Carbonylated protein concentrations in bron-
choalveolar lavage of patients with different interstitial lung
diseases (S: sarcoidosis; SSc: pulmonary fibrosis associated with
systemic sclerosis; IPF: idiopathic pulmonary fibrosis; EAA:
extrinsic allergic alveolitis; CEP: chronic eosinophilic pneu-
monia) (see Ref. 39).was a selective process involving certain proteins crucial in
fibrogenesis that were oxidized in IPF but not in sarcoidosis
or systemic sclerosis patients (Fig. 3).22 Albumin, immuno-
globulins and complement C3 were carbonylated in BAL of
Ssc. In IPF patients, complement C3, transferrin, immuno-
globulin light chains, immunoglobulin A and a group of six
plasma proteins were the protein targets of carbonylation.
In sarcoidosis patients, albumin, immunoglobulins, alpha1-
antitrypsin, complement C3 were found to be oxidized.22
These results and other evidence suggested different
patterns of oxidation and antioxidant responses in different
DLD. The specific pathogenetic mechanisms are associated
with different inflammatory cells recruited in each DLD,
resulting in carbonylation of different targets of oxidation
that enables identification of oxidation profiles character-
istic of the various diseases.17,22 Some antioxidant enzymes
and numerous proteolytic fragments of apolipoprotein A1,
haptoglobin b, serotransferrin and a-1-antitrypsin have
been observed specifically in BAL of IPF patients and not in
other DLDs, indicating the high proteolytic activity typical
of IPF.17,18
Elevated oxidative and nitrosative stress in idiopathic
pulmonary fibrosis has also been demonstrated by
increased levels of H2O2 in expired breath condensate,
33
increased eosinophilic mediators and myeloperoxidase
concentrations in BAL,34 enhanced levels of lipid perox-
idation products (such as 8-isoprostane) in BAL and
condensate35 and elevated nitric oxide concentrations in
exhaled breath.34e39
Interactions of ROS/RNS with the protease/
antiprotease system
Extracellular matrix degradation mediated by
ROS/RNS and protease/antiprotease system. Role
of matrix metalloproteinases and plasminogen
activator inhibitor 1
Altered mechanisms of extracellular matrix degradation in
patients with DLD may lead to irreversible fibrotic lung
damage. It has been demonstrated that the structural
remodelling occurring in these diseases is mediated by
matrix metalloproteinases (MMPs) and their specific inhib-
itors (tissue inhibitors of metalloproteases (TIMPs).40
Protease and antiprotease expression in tissue and BAL of
IPF patients suggests increases in different proteases,
particularly matrix metalloproteinase-7 (or matrilysin) that
contributes to lung epithelial damage in IPF.23,40,41 Oxidant
radicals participate in protease/antiprotease imbalance by
activating MMPs through modification of their cysteine
domain and inactivating TIMPs.40,41 ROS can also directly
induce MMP gene transcription.40 ROS/RNS may also inac-
tivate the protease system. MMP activation or inactivation
is determined on the basis of local concentrations.7,9,40 The
main antioxidant enzymes inhibiting oxidative activation of
MMPs are glutathione peroxidase and extracellular super-
oxide dismutase (EC-SOD).42,43
Degradation of the extracellular matrix is also triggered
by plasmin. Activation of tissue-type plasminogen acti-
vator (t-PA) and urokinase-type plasminogen activator
(u-PA) is normally regulated by plasminogen activator
Figure 3 Proteomic analysis of bronchoalveolar lavage from patients with idiopathic pulmonary fibrosis, sarcoidosis and
pulmonary fibrosis associated with systemic sclerosis. On the right: list of carbonylated proteins observed by immunoblot analysis
and their corresponding frequencies in healthy subjects and patients with sarcoidosis, Ssc and IPF. On the left: carbonylated
proteins are indicated with arrows (see Ref. 22).
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of the extracellular matrix.7 In IPF, abnormal repair of
lung tissue may be the consequence of altered activation
of PAI-1 activity, as recently reported by Liu.44 Reactive
oxygen species upregulate the transcription rate of the
PAI-1 gene by activating mitogen-activated protein kinase
pathways and/or the NF-kB pathway. PAI-1 plays a pivotal
role in the development of lung fibrosis and ROS/RNS
mediate induction of PAI-1 through different growth
factors, cytokines, and other agents.44 ROS/RNS are
modulators of protease/antiprotease balance which
contribute to extracellular matrix degradation, a key event
in the pulmonary structural remodelling occurring in
diffuse lung diseases.7,9,23,40e44ROS/RNS regulation of apoptosis
 Apoptosis mediators
 Apoptosis in IPF
 Apoptosis induced by ROS/RNS in DLD
Apoptosis (programmed cell death) manifests through
a highly conserved signalling pathway. It plays an important
role in normal lung homeostasis, participating in the path-
ogenesis of a variety of lung diseases, including fibrotic lung
disorders.45e47
Caspase family protein is crucial in apoptosis. Pro-cas-
pases (inactive cytoplasmic forms) activated through
extrinsic or intrinsic pathways can migrate to the nucleus,
causing the ultimate breakdown of the cell.45 The extrinsic
pathway depends on activation of members of the TNF
receptor superfamily (including Fas/CD95) that bind ligands(e.g. FasL) in the extracellular space, creating Fas-associ-
ated death domains (FADD) and activating caspases 8 and
10 and subsequently caspases 3 and 7 that promote
apoptosis directly (Fig. 4).45 The intrinsic pathway is due to
internal cell stressors (such as DNA damage) that activate
proapoptotic Bcl-2 proteins (e.g. Bax, Bac) and/or inacti-
vate antiapoptotic Bcl-2 proteins (e.g. Bcl-2 itself) leading
to mitochondrial release of cytochrome c, activation of
caspase 9 and consequently caspase 3 and 7 that cause
apoptosis (Fig. 4).45 Activation of caspases may be inhibited
by various molecules, including inhibitors of apoptosis
IAP.48
Alveolar epithelial cell apoptosis by the FaseFasL
pathway has been documented in pulmonary fibrosis46,47,49
in which proapoptotic mediators (p53, p21, Bax) and cas-
pase 3 were found to be upregulated while Bcl-2 and other
antiapoptotic molecules were downregulated.50 TGF-beta 1
is an inductor of alveolar epithelial cell apoptosis through
caspase activation, upregulation of p21 and downregulation
of antiapoptotic Bcl-251; this cytokine also inhibits fibro-
blast apoptotic phenomena in animal models of lung fibrosis
and induces ROS/RNS production by fibroblasts.52 In IPF,
fibroblasts have been found resistant to Fas-mediated
apoptosis due to an increase in Fas-activated FADD-like IL-
1-converting enzyme-like inhibitory of apoptosis protein
(FLIP).53,54
Kuwano et al. demonstrated an association between
increased mitochondrial generation of reactive oxygen
species and apoptosis of alveolar epithelial cells in IPF
patients.49 Loss of epithelial cells leads to destruction of
alveolar basement membrane and recruitment of fibro-
blasts in situ to repair the damage by deposition of extra-
cellular matrix. The resistance of fibroblasts to apoptosis
Figure 4 Apoptosis in alveolar epithelial cells of patients with idiopathic pulmonary fibrosis (IPF): intrinsic and extrinsic path-
ways and ROS involvement in apoptotic mechanisms. ROSZ reactive oxygen species; p38 MAPKZ p38 mitogen-activated protein
kinase; SmadsZmothers against decapentaplegia in Drosophila (Mad ) gene and the related Sma gene in Caenorlabditis elegans;
FasLZ Fas ligand; FasZ apoptosis-mediating surface antigen (aka Apo-1 and CD95); FADDZ Fas-associated death domain;
BAXZ BCL-2-associated protein; BCL-2Z B-cell lymphoma 2; ATIIZ angiotensin II; ARZ angiotensin receptor (subtype I).
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quent destruction of normal lung architecture.45 ROS/RNS
may upregulate cell death by interacting with caspase 3,
inducing cytochrome c release from mitochondria, inducing
DNA fragmentation and activation of mitogen-activated
protein kinase (MAPK) pathway with subsequent activation
of ERK, JNK and p38 MAPK (reviewed in Ref. 55). Stimula-
tion of receptor tyrosine kinases or activation of protein
kinase C-mediated pathways has also been associated with
oxidant-induced apoptosis.48 All these molecular alter-
ations have been documented by enhanced apoptosis in
lungs of IPF patients at bronchiolar and alveolar levels.48
Many intracellular signalling pathways implicated in
ROS-mediated apoptosis are active in IPF.47,48 Thioredoxin 1
(see the section ‘‘Antioxidant protection and diffuse lung
diseases’’) is a radical scavenger, reported to protect the
lungs of transgenic mice against hyperoxia-induced oxida-
tive damage and to prevent apoptosis of alveolar epithelial
cells by inducing upregulation of the antiapoptotic medi-
ator Bcl-2.56 ROS/RNS regulation of apoptosis in idiopathic
pulmonary fibrosis is reported in Fig. 4.Interactions of ROS/RNS with mediators of
diffuse lung diseases
 TGF-b interactions with ROS/RNS in IPF
 Other cytokines associated with oxidative stress in DLD
Transforming growth factor-b (TGF-b) is an important pro-
fibrotic growth factor with several immunological functions,involved in the aberrant lung repair mechanism character-
istic of many fibrotic lung disorders.57e60 Transforming
growth factor-b is synthesized as inactive precursor and
secreted as part of a latent complex: L-TGF-b. Immediately
after lung injury, this cytokine exerts its proinflammatory
and chemotactic activities by recruiting myofibroblasts.61 In
advanced stages of injury (i.e. lung fibrosis) it participates
in lung tissue repair, mediating abnormal remodelling.7 This
profibrotic growth factor is over-expressed in IPF tissues by
type II epithelial cells, fibroblasts and alveolar macro-
phages.57 The persistence of this cytokine enhances
activation of immunoinflammatory cells, alters synthesis,
deposition and turnover of matrix components and stimu-
lates over-production of type I and type III collagen by
different types of cells.48,53 Myofibroblast activation and
production of extracellular matrix in the lung may be the
consequence of persistently elevated TGF-b levels.7
TGF-b may induce over-production of reactive oxygen
species in IPF by activation of NADPH oxidase; at the same
time ROS can activate latent TGF-beta 1, upregulating TGF-
b expression.62,63 Since TGF-beta is a potent inhibitor of
glutathione synthesis, it also promotes the antioxidant
deficit typical of IPF.64 On the other hand, extracellular
superoxide dismutase prevents lung injury and stabilizes
extracellular matrix components, inactivating TGF-b.65
Oxidants/antioxidants can interact with different
mediators of DLD; for example ROS generated by silica
particles and by silica-activated cells can induce expression
of several inflammatory cytokines, such as TNF-a, TGF-
b and IL-1b, responsible for lung damage and progression of
fibrotic disease.66,67 Some authors also report correlations
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cytokines in different DLD. Lenz and coworkers reported an
inverse correlation between BAL carbonyl levels and INF-g
concentrations in sarcoidosis and a low IL-10/IL-8 mRNA
ratio in BAL cells of IPF patient.23 IL12 is a Th1 proin-
flammatory cytokine that is elevated in Sjogren Syndrome.
Overexpression of IL12 in lung tissues of mice has been
associated with increased oxidative stress (evaluated by
nitrotyrosine staining).68
Antioxidant protection and diffuse lung
diseases
 Main non-enzymic antioxidants of the lungs and DLD
 Main antioxidant enzymes in health and DLD and the
regulatory function of NRF2
1. Superoxide dismutases (SODs):
- Extracellular superoxide dismutase (EC-SOD)
- Copper/zinc superoxide dismutase (Cu/Zn-SOD)
- Manganese superoxide dismutase (Mn-SOD)
2. Catalase
3. Glutathione and glutathione peroxidase
4. Peroxyredoxins
5. Thioredoxins
6. Glutaredoxins
7. Heme oxygenases
Certain low molecular weight compounds exert antioxi-
dant functions under physiological conditions. Non-enzymic
molecules involved in defence against oxidants include
vitamins, such as vitamin C and vitamin E, beta carotene,
retinol, uric acid and glutathione (see below).9 The anti-
oxidant properties of vitamin E on bleomycin-induced lung
fibrosis have been documented. Infusion of high doses of
vitamin E considerably reduces the fibrotic effects of
bleomycin on mouse lung tissue by reducing the hydrox-
yproline/soluble protein ratio.69 A more recent research
showed an inverse correlation between mortality risk and
plasma concentrations of retinol and vitamin E in a pop-
ulation of patients with asbestosis.70
The lungs are protected from the negative effects of
oxidant persistence in tissues by endogenous agents named
antioxidants. Antioxidants may be non-enzyme or enzyme
proteins. The former include glutathione, vitamins (alpha-
tocopherol and ascorbic acid), beta carotene and uric acid;
the latter, superoxide dismutases, catalases and peroxi-
dases.9,71 Proteins crucial in cellular antioxidant defences
are: peroxyredoxins, thioredoxins, glutaredoxins and heme
oxygenases.9,17,18 Here we describe the principal antioxi-
dant enzymes in the lungs and discuss their potential
involvement in diffuse lung diseases.
Superoxide dismutases (SODs)
Extracellular-SOD (EC-SOD), copper/zinc-SOD (Cu/Zn-SOD)
and manganese-SOD (Mn-SOD) are different superoxide
dismutases that protect the lungs against oxidative stress
by reducing superoxide anion to hydrogen peroxide, which
is then converted to water by catalase and glutathione
peroxidase.9 The role of SODs in the pathogenesis of
chronic inflammatory lung disorders has been widely
described in the recent literature.65,72,73EC-SOD is a slightly hydrophobic glycoprotein that binds
cell surfaces and matrix components. Expression of EC-SOD
is cell- and tissue-specific and is found predominantly in
lungs, heart, blood vessels, placenta and kidneys. In normal
lung tissue, EC-SOD is expressed by alveolar macrophages,
bronchial epithelium, vascular endothelium, extracellular
matrix and epithelial cells.9
EC-SOD normally protects the lungs against fibrosis by
preventing oxidative degradation of the matrix and by
binding type I and type IV collagen via its heparin/matrix
binding domain.65 Its expression has been evaluated in lung
tissue samples from patients with extrinsic allergic alveo-
litis (EAA), sarcoidosis, IPF, desquamative interstitial
pneumonia (DIP) and chronic obstructive pulmonary disease
(COPD).9,74 The authors demonstrated lower immunoreac-
tivity for EC-SOD in DLD patients than controls, suggesting
the possibility of its involvement in the pathogenesis of
DLD.74 In IPF, EC-SOD is practically absent in fibrotic areas
and fibroblast foci, suggesting that it is depleted where the
oxidative burst is particularly strong.74 The prospect that
EC-SOD is downregulated in IPF while its copper/zinc and
manganese forms are upregulated in lung diseases is an
intriguing topic.74,75 Its decrease in IPF could be due to the
extremely high concentrations of oxidants in this severe
DLD and also to EC-SOD localisation in the extracellular
matrix and cell surface, trigger points for oxidative-medi-
ated lung damage in IPF.39,65,75 In IPF, many matrix
components are sensitive to oxidative modification/degra-
dation and a significantly elevated turnover of extracellular
matrix has been reported; EC-SOD reduction is therefore
clearly associated with increased risk of oxidative stress-
mediated matrix degradation in this disease.65
Copper/zinc superoxide dismutase is located in epithe-
lial cells, fibroblasts and alveolar macrophages.9 Its main
function is to scavenge O2
, inhibiting redox generation of
ROS and RNS.9 Positive immunoreactivity of this enzyme has
been documented in bronchial epithelium of sarcoidosis
and extrinsic allergic alveolitis patients.76 Although the
exact pathogenetic role of this enzyme in oxidative-medi-
ated lung injury is still unclear, its concentrations in serum
from idiopathic pulmonary fibrosis patients have been
found elevated with respect to controls.72
Manganese superoxide dismutase is an 88-kDa protein
expressed by polymorphonuclear cells, bronchial epithelial
cells, endothelial cells and pneumocytes.77 Gene expression
of this protein is stimulated by increased exogenous and
endogenous oxidants in the airways. Increased concentra-
tions of Mn-SOD were reported by Harju and colleagues in
healthy smokers.75 Chang et al. evaluated expression of
Mn-SOD in lung tissue of rats exposed to hyperoxia.76
Mn-SOD is over-expressed by alveolar macrophages in
sarcoidosis and extrinsic allergic alveolitis granulomas
through cytokine-mediated induction during granuloma
formation.78,79 In lung tissue of IPF patients, increased
expression of Mn-SOD is reported in type II pneumocytes
and alveolar macrophages.79 Mild expression of Mn-SOD is
described in alveolar type II epithelial cells and macro-
phages from DIP samples.72,79
Catalase
Catalase is a 240-kDa protein mainly found in macrophages,
pneumocytes and lung fibroblasts. It exerts its antioxidant
1252 E. Bargagli et al.function by reducing hydrogen peroxide (produced by SODs)
to water. The real involvement of this enzyme in oxidative
lung damage is still unclear and controversial data is
available on oxidant-mediated catalase production.9
In 2000 Lakari et al. evaluated catalase and Mn-SOD
expression by immunohistochemistry in lung tissue from
patients with IPF, DIP, EAA and sarcoidosis.79 Catalase and
Mn-SOD were expressed in alveolar regions of DIP and usual
interstitial pneumonia (UIP) and in granulomas of sarcoid-
osis and extrinsic allergic alveolitis, suggesting a protective
role against progression of diffuse lung diseases.79 The role
of catalase, SODs and antioxidant enzymes in the patho-
genesis of Ssc was recently reviewed by Gabrielli et al.80 A
significant reduction in catalase and SOD levels in blood of
Ssc patients has been reported.16,80
Glutathione and glutathione peroxidase
The physiological antioxidant role of this tetrameric protein
is much better described than that of catalase.9 In normal
conditions, bronchial epithelial cells, alveolar macrophages
and other cell lines synthesize glutathione, that it is
generally abundant in epithelial lining fluid of normal lungs.
Its main function is to convert hydroperoxides to less
dangerous hydroxides, protecting cells against oxidative
damage (Fig. 5).9 Glutathione peroxidases are a family of
enzymes including three selenium-dependent enzymes and
one selenium-independent antioxidant peroxidase. The
glutathione peroxidases are divided into cellular and
extracellular forms.9 The extracellular form of selenium-
dependent glutathione peroxidase is mainly located in
epithelial lining fluid together with glutathione and is
produced by bronchial epithelial cells and alveolar macro-
phages.9 Its main function is to protect alveolar epithelial
cells against oxidative stress, such as hyperoxia-induced
lung damage.9 The activity of the extracellular glutathione
peroxidase appears to be enhanced in sputum from patients
with cystic fibrosis.81
Glutathione and glutathione peroxidase levels are
elevated in various granulomatous lung diseases, including
chronic beryllium disease.82 Glutathione metabolism isFigure 5 Glutathione cycle. Glutathione peroxidase (GP)
catalyzes oxidation of glutathione (GSH) to its oxidized form
(GSSG), scavenging hydrogen peroxide (H2O2). GSSG is recon-
verted to GSH by glutathione reductase (GR).altered in IPF: in this disease BAL glutathione levels are
lower than in controls and administration of N-acetylcys-
teine (NAC) stimulates glutathione synthesis, partially
restoring glutathione levels at alveolar level.83e86 In vivo
experiments in bleomycin-induced lung fibrosis have
confirmed that N-acetylcysteine reduces the primary
inflammatory events, preventing cell damage and devel-
opment of IPF.87
Peroxyredoxins
Peroxyredoxins are a group of antioxidant enzymes involved
in the breakdown of hydrogen peroxide. Six different types
of peroxyredoxins (IeVI) have been characterized in human
lungs. They protect lungs against oxidative stress by
reducing a wide spectrum of peroxides.8 Peroxyredoxin 1 is
mainly expressed by bronchial epithelial cells and alveolar
macrophages. Peroxyredoxin 2 is expressed by alveolar type
II cells and is associated with platelet-derived growth factor
(PDGF) signalling and cell proliferation.56 The peroxyr-
edoxins mainly expressed in the lungs are peroxyredoxins 3,
5 and 7, typically found in bronchial and alveolar epithelial
cells and macrophages.8,9 Increased expression of different
peroxyredoxins has been reported in lung cancer, alveolitis
and hypoxic conditions.9 The potential role of peroxyr-
edoxins in the pathogenesis of diffuse lung diseases is still
unclear. Recently Vuorinen and colleagues observed that
peroxyredoxin 2 was mainly localised in lung epithelium and
alveolar macrophages of IPF patients with very low
expression by cells of fibroblastic foci.88
Thioredoxins
Bronchial epithelium and alveolar macrophages are the
main sources of thioredoxins in the lungs. This group of
oxido-reductases (derived from the flavoprotein family) is
composed of thioredoxin and thioredoxin reductase
components.9,89 The major functions of these enzymes are
regulation of cell proliferation in the presence of NADPe
NADPH, chemotactic activity, suppression of leukocyte
infiltration into sites of inflammation, NF-kB activation and
protection of tissues against exogenous oxidants.89 Thio-
redoxin has been observed to reduce the viscosity of
sputum in cystic fibrosis patients and airway inflammation
and hyper-reactivity in asthmatics.90,91 Expression of these
enzymes in lung tissue of patients with DLD was analysed by
immunohistochemistry by Tiitto et al.92 Thioredoxin and
thioredoxin reductase were highly concentrated in areas of
metaplastic epithelium from IPF patients (but almost
absent in fibrotic areas), in alveolar macrophages from DIP
patients and in granulomas of sarcoidosis patients, sug-
gesting involvement of thioredoxins in ongoing cell regen-
eration and inflammation.92 Thioredoxin-transgenic mice
and mice receiving thioredoxin treatment showed
decreased bleomycin-induced cellular infiltrates and
fibrotic changes in lung tissue in the bleomycin-induced
lung fibrosis model.9,89 Kinnula et al. reported that thio-
redoxins and thioredoxin reductase were expressed in
metaplastic epithelium from UIP tissue samples but were
absent in areas of active fibrosis, suggesting elevated
oxidant generation in IPF.8
Glutaredoxins
Glutaredoxins (Grx1 cytosolic, Grx2 mitochondrial)
preserve the ideal redox state of cells by reducing protein
Oxidative stress in diffuse lung diseases 1253disulphides to sulphydryls. They are expressed abundantly
by alveolar cells, bronchial epithelial cells and lung
macrophages.8,93 The large quantity of Grx1 in alveolar
macrophages of healthy lung tissue suggests a fundamental
role of this protein in the physiological regulation of
oxidant/antioxidant balance. Several cytokines activate
Grx1 expression and TGF-beta downregulates its expres-
sion, as demonstrated in vivo in experiments with intersti-
tial lung diseases.93 In pulmonary sarcoidosis, allergic
alveolitis and lung fibrosis, expression of glutaredoxins is
much reduced with consequent loss of antioxidant
defences.94
Heme oxygenases
Heme oxygenase-1 (HO-1) is a 30-kDa protein that exerts
antiapoptotic, anti-inflammatory and antioxidant activities
by converting heme to carbon monoxide and biliverdin.
Alveolar macrophages, bronchial epithelial cells and
inflammatory cells release HO-1 under different stim-
uli.95e97 Heme oxygenase knockout mice are very sensitive
to oxidative stress.96 HO-1 is an inducible isoform of heme
oxygenase thought to be an oxidative stress-responsive
protein. It has been found upregulated in smokers and
patients with asthma, acute lung injury, cystic fibrosis or
chronic rejection of lung transplant, and downregulated in
severe chronic obstructive pulmonary disease.9,95e97
Protective effects of HO-1 have also been proposed in
asbestosis and silicosis.97 Sato et al. reported that it
attenuates chronic silicosis in mice and humans by sup-
pressing ROS activities; its expression was found enhanced
in this disease and the enzyme may therefore be regarded
as a potential marker of disease severity.97 There is
evidence that HO is a heat-shock antioxidant protein mainly
expressed in the inflammatory phases of DLD.9 An inter-
esting study by Ye et al. showed that HO-1 was depleted in
BAL cells of IPF patients, supporting the hypothesis that an
oxidative imbalance is responsible for progression of IPF.95
Protective functions of HO-1 in the respiratory system were
reviewed by Ryter et al. in 2007.96 The anti-inflammatory
cytokine IL-10, hyperoxia, exogenous nitric oxide, diesel
exhaust particles and quinones are stimuli that induce HO-1
expression.98 Molecules inhibiting HO-1 expression and
activity include proinflammatory cytokines (IL-1, IL-17,
TNF-a) and zinc-deuteroporphyrin.99 The expression of HO-
1, thioredoxins and other antioxidant enzymes is regulated
by nuclear factor-erythroid 2 p45 subunit-related factor 2
(NRF2), a transcriptional factor activating antioxidant
responses. Its function is essential for defence against ROS/
RNS damage.100 NRF2 may be suppressed by the enzyme
Kelch-like enoyl-CoA hydratase-associated protein 1
(Keap1) that sequesters NRF2 in cytoplasm by creating an
inactive Keap1/NRF2 complex. In response to oxidative
stress, NRF2 (dissociated from Keap1) binds specific anti-
oxidant elements in antioxidant enzyme promoter and
defence protein genes and regulates their expression in
many tissues.100,101 In this way NRF2 protects against
oxidant-mediated lung injury and influences susceptibility
to IPF.43 Studies on animal models have shown that NRF2
protects against fibrogenesis: mouse models, knockout for
NRF2, showed significantly reduced antioxidant activities
and enhanced susceptibility to bleomycin-induced lung
fibrosis.43Conclusion
 Oxidative stress in the pathogenesis of DLD
 Future therapeutic approach
Oxygen-derived free radicals produced by phagocytes are
believed to contribute to lung tissue damage occurring in
DLD. A lung defence mechanism against oxidative stress
produces antioxidant molecules. Bronchoalveolar lavage
protein composition shows different protein profiles with
different levels of antioxidant proteins in sarcoidosis, IPF
and Ssc.17,102 Different pathways counteracting oxidative-
mediated tissue damage have therefore been hypothesised
for different lung pathogenesis.22 Detailed analysis of
oxidant and antioxidant molecules in DLD corroborates the
hypothesis that different DLD have specific patterns of
oxidant-mediated lung injury and antioxidant defences.22
However, oxidant/antioxidant imbalance has been thor-
oughly investigated for some DLD (such as IPF) while very
little data is available for others. Better knowledge of the
antioxidant enzymes involved in the regulation of cell redox
status in DLD could enable potential new biomarkers of lung
disease severity and activity to be identified, just as heme
oxygenase-1 was found to be a biomarker of silicosis.96 The
study of oxidative stress in the pathogenesis of DLD could
open new therapeutic horizons. Recent attempts to correct
oxidant/antioxidant imbalance in DLD83e86,94,103 showed
that high doses of antioxidants (which can prevent
epithelial cell damage by oxygen radicals) could reverse
extracellular glutathione deficiency and oxidative damage
in patients with IPF. As oxidative stress has been associated
with the pathogenesis of DLD such as sarcoidosis, pulmo-
nary fibrosis associated with systemic sclerosis and pneu-
moconiosis, novel clinical trials to verify the effectiveness
of antioxidants in these diseases are urgently required.
In conclusion, research into oxidant/antioxidant balance
in diffuse lung diseases is a promising field that can provide
insights into pathogenetic mechanisms and open new
therapeutic perspectives.Conflict of interest
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